4-[1-(tert-butoxycarbonyl)]piperidine acetic acid | 1154101-11-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-[1-(tert-butoxycarbonyl)]piperidine acetic acid
• 英文别名: 4-(Carboxymethyl-amino)-piperidine-1-carboxylic acid tert-butyl ester；2-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]amino]acetic acid
• CAS: 1154101-11-7
• 化学式: C₁₂H₂₂N₂O₄
• 分子量: 258.318
• InChiKey: SUFIIFMQXYDGSR-UHFFFAOYSA-N

物化性质

• 沸点：
  395.8±37.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[1-(tert-butoxycarbonyl)]piperidine acetic acid 、 acetic acid mutilin11-ester 在 sodium azide 、 氯甲酸乙酯 、 三乙胺 、 吡啶 、 4-二甲氨基吡啶 作用下， 以 水 、 丙酮 、 甲苯 为溶剂， 反应 3.5h， 生成 [[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl]carbamic acid 11-acetyloxy mutilin14-ester
  参考文献：
  名称：

  WO2007/37518

  摘要：

  公开号：

文献信息

• Certain azacycloalkyl substituted acetic acid derivatives
  申请人：——

  公开号：US20040235896A1

  公开（公告）日：2004-11-25

  Compounds of the formula (I) wherein R represents OH or NHOH; R 1 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid of from a sulfonic acid; R 2 represents biarylsulfonyl or aryloxyarylsufonyl; R 3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or form a carbamic acid; R 4 and R 5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals. 1

  式(I)化合物，其中R代表OH或NHOH；R1代表氢、可选择性取代的低级烷基、芳基-低级烷基、环烷基-低级烷基或源自羧酸、碳酸、氨基甲酸或磺酸的酰基；R2代表双芳基磺酰基或芳氧基芳基磺酰基；R3代表氢、可选择性取代的低级烷基、芳基-低级烷基、环烷基-低级烷基或源自羧酸、碳酸或氨基甲酸的酰基；R4和R5各自独立地代表氢、低级烷基、低级烷氧羰基、芳基-低级烷基或环烷基-低级烷基；m为0、1、2或3；其药学上可接受的药物前体衍生物；其药学上可接受的盐；包含所述化合物的药物组合物；以及它们用于抑制基质降解金属蛋白酶和预防或治疗哺乳动物中依赖基质金属蛋白酶的状况的用途。
• HCV NS3 protease inhibitors
  申请人：Holloway M. Katharine

  公开号：US20090075869A1

  公开（公告）日：2009-03-19

  The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

  本发明涉及公式（I）的大环化合物，其可用作丙型肝炎病毒（HCV）NS3蛋白酶的抑制剂，其合成以及其用于治疗或预防HCV感染的用途。
• Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors
  申请人：Fujimoto Aki Roger

  公开号：US20070060569A1

  公开（公告）日：2007-03-15

  Compound of the formula wherein R represents OH or NHOH; R 1 represents hydrogen, optically substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid or from a sulfonic acid; R 2 represents biarylsulfonyl or aryloxyrylsulfonyl; R 3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or from a carbamic acid; R 4 and R 5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals.

  该公式的化合物中，R代表OH或NHOH; R1代表氢、光学取代的较低烷基、芳基-较低烷基、环烷基-较低烷基或由羧酸、碳酸、氨基甲酸或磺酸衍生的酰基; R2代表双芳基磺酰基或芳氧基芳基磺酰基; R3代表氢、可选取代的较低烷基、芳基-较低烷基、环烷基-较低烷基或由羧酸、碳酸或氨基甲酸衍生的酰基; R4和R5分别独立地代表氢、较低烷基、较低烷氧羰基、芳基-较低烷基或环烷基-较低烷基; m为零、1、2或3; 其药物可接受的前药衍生物; 其药物可接受的盐; 包括所述化合物的制药组合物; 以及它们用于抑制基质降解金属蛋白酶并预防或治疗哺乳动物基质金属蛋白酶依赖性疾病的用途。
• Synthesis of enantiomerically enriched 4-piperidinylglycine
  申请人：——

  公开号：US20020133014A1

  公开（公告）日：2002-09-19

  A process for making enantiomerically enriched 4-piperidinylglycine having the formula (I), 1 said process comprising (a) combining N-protected glycine ester with 4-piperidone to form didehydroamino acid ester; (b) reducing the didehydroamino acid ester with hydrogen gas in the presence of a rhodium catalyst selected from the group consisting of (R,R)-BPE-Rh; (S,S)-BPE-Rh; (R,R)-DuPHOS-Rh; (S,S)-DuPHOS-Rh; and combinations thereof; whereby a protected compound is formed; and (c) removing the protecting groups from the protected compound, whereby the 4-piperidinylglyeine having the formula (I) is formed, wherein X − is an anion wherein X is independently a halogen; and “*” designates an asymmetric carbon having (R)- or (S)-configuration. The process of the invention yields an enantiomerically enriched (R)-4-piperidineglycine or (S)-4-piperidineglycine.

  一种制备对映富集的4-哌啶基甘氨酸(I)的方法，该方法包括(a)将N-保护的甘氨酸酯与4-哌酮结合形成双脱水氨基酸酯；(b)在(R,R)-BPE-Rh、(S,S)-BPE-Rh、(R,R)-DuPHOS-Rh、(S,S)-DuPHOS-Rh或其组合物中选择一个铑催化剂，在氢气存在下还原双脱水氨基酸酯，形成保护化合物；(c)从保护化合物中去除保护基，从而形成式(I)的4-哌啶基甘氨酸，其中X-是一个阴离子，其中X独立地是卤素；“*”表示具有(R)-或(S)-构型的不对称碳。该发明的方法产生对映富集的(R)-4-哌啶基甘氨酸或(S)-4-哌啶基甘氨酸。
• NOVEL COMPOUND HAVING PLATELET AGGREGATION INHIBITOR EFFECT
  申请人：MEIJI SEIKA KABUSHIKI KAISHA

  公开号：EP0721941A1

  公开（公告）日：1996-07-17

  A compound represented by general formula (I) and having a platelet aggregation inhibitor effect and pharmacologically acceptable salt and solvate thereof, wherein A, B and C represent each CH2 or C=O; X and Y are different from each other and represent CH or N; D represents -(CH2)k- or -(CH2)m-CO-, wherein k represents an integer of 1 to 4, and m represents an integer of 0 to 3; E represents group (II) or (III), wherein n represents an integer of 1 to 3, Z represents -W-(CH2)p-COOR3, W represents -O- or a bond, p represents an integer of 1 to 4, and R3 represents hydrogen, lower alkyl or an ester residue eliminable under physiological conditions; R1 represents hydrogen or lower alkyl; and R2 represents hydrogen or lower alkyl.

  通式(I)代表的具有血小板聚集抑制作用的化合物及其药理学上可接受的盐和溶液，其中A、B和C分别代表CH2或C＝O；X和Y互不相同，代表CH或N；D代表-( )k-或-( )m-CO-，其中k代表1至4的整数，m代表0至3的整数；E 代表基团(II)或(III)，其中 n 代表 1 至 3 的整数，Z 代表-W-( )p-COOR3，W 代表-O-或键，p 代表 1 至 4 的整数，R3 代表氢、低级烷基或在生理条件下可消除的酯残基；R1 代表氢或低级烷基；R2 代表氢或低级烷基。